The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with STX209. These same subjects will also be asked to contribute a blood sample for DNA (deoxyribonucleic acid) collection. The investigators will study the DNA to determine if STX209 works better in people with specific gene variations, or to find new gene variations that predict how well STX209 works.
Study Type
OBSERVATIONAL
Enrollment
32
collection of serum for DNA to elucidate a potential biomarker for patients with ASD
Southwest Autism Research & Resource Center
Phoenix, Arizona, United States
University of California-Los Angeles Neuropsychiatric Institute
Los Angeles, California, United States
Yale Child Study Center
New Haven, Connecticut, United States
Riley Hospital for Children
Indianapolis, Indiana, United States
University of North Carolina Neurosciences Hospital
Chapel Hill, North Carolina, United States
Vanderbilt Kennedy Center
Nashville, Tennessee, United States
Red Oaks Psychiatry Associates, PA
Houston, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Biomarker
evaluation of DNA for ASD to elucidate a potential biomaker
Time frame: june 2013
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.